Seattle Genetics nets $12 million up front in deal expansion with Genentech
This article was originally published in Scrip
Executive Summary
Seattle Genetics has expanded its antibody-drug conjugate (ADC) collaboration agreement with Genentech (Roche), netting a further $12 million up front under the expanded deal.